Biotech Values

[DewDiligence]

MNTA’s cancer program is rarely mentioned because the company has so many other moving parts; however, Craig Wheeler talked about the cancer program at the very end of today’s JPM webcast.

The rationale for the program is simple: some of the SoC anticoagulant drugs have profound anti-tumor activity, but such drugs can’t be properly dosed for activity against cancer because these doses would cause patients to bleed to death.

Using the same technology that allowed MNTA to characterize Lovenox and to engineer M118 from the components of unfractionated heparin, MNTA’s engineers have modified the heparin mixture to remove the components that cause anticoagulation while keeping or even enhancing the components that have anti-tumor activity.